Wolverine Trading’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Wolverine Trading’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-7,260	Closed	-$213K	–	7296
2021 Q2	$236K	Sell	7,260 -5,301	-42%	-$207K	﹤0.01%	4800
2021 Q1	$512K	Sell	12,561 -11,523	-48%	-$530K	﹤0.01%	3664
2020 Q4	$1.07M	Buy	24,084 +13,017	+118%	+$642K	﹤0.01%	2301
2020 Q3	$597K	Buy	+11,067	New	+$703K	﹤0.01%	2618
2020 Q2	–	Sell	-27,672	Closed	-$1.44M	–	5471
2020 Q1	$1.44M	Buy	27,672 +19,963	+259%	+$1.34M	﹤0.01%	1620
2019 Q4	$610K	Buy	7,709 +277	+4%	+$16.4K	﹤0.01%	2891
2019 Q3	$366K	Sell	7,432 -163	-2%	-$8.49K	﹤0.01%	2959
2019 Q2	$399K	Sell	7,595 -465	-6%	-$26.7K	﹤0.01%	2954
2019 Q1	$427K	Sell	8,060 -12,435	-61%	-$611K	﹤0.01%	2952
2018 Q4	$820K	Buy	20,495 +13,066	+176%	+$490K	﹤0.01%	2152
2018 Q3	$282K	Buy	+7,429	New	+$329K	﹤0.01%	3813

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Wolverine Trading's GBT Position: Q3 2021 in Review

Wolverine Trading sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2021, closing a stake of 7,260 shares — an estimated $213K sold.

Wolverine Trading first reported a position in GBT in Q3 2018 and held it in 11 quarters. The position peaked at $1.44M in Q1 2020. 187 funds tracked by Wall St. Rank hold GBT as of Q3 2021.

Wolverine Trading reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
Wolverine Trading sold 7,260 Global Blood Therapeutics, Inc. shares in Q3 2021, an estimated $213K.
Wolverine Trading first reported a position in Global Blood Therapeutics, Inc. in Q3 2018 and held it in 11 quarters.
Wolverine Trading's Global Blood Therapeutics, Inc. position peaked at $1.44M in Q1 2020.
187 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2021.

Based on Wolverine Trading's 13F filing for Q3 2021, filed 12 Nov 2021.